Presbyopia Market

DelveInsight’s ‘Presbyopia - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Presbyopia market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted 7MM Presbyopia market size from 2019 to 2032. The Report also covers current Presbyopia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032

Presbyopia Disease Understanding and Treatment Algorithm

Presbyopia Overview

Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.

It is mostly due to age-related changes that the proteins within the lens of the eye become thicker, harder, and less flexible. This loss of flexibility affects the lens's ability to refract light rays which, in turn, affects the eye's capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect. According to type, Presbyopia can be classified into incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia

Initial symptoms include difficulties with prolonged close-up work along with tiring of the eyes. Other common symptoms are delays in focusing at near or distance, ocular discomfort, headache, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, need for brighter light for reading, and diplopia. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work.

Presbyopia Diagnosis

A basic and comprehensive examination of the eye with a series of different tests is necessary to diagnose presbyopia. The ophthalmologist examines the retina and conducts muscle integrity, refraction, slit-lamp, visual field, and visual acuity tests. These will help to ascertain the condition. Eye drops used during this process to dilate the pupils will cause patients to experience increased sensitivity to light in the few hours following the examinations.

With the help of an ophthalmoscope, the specialist can evaluate the retina, optic disk, and choroid (i.e. a layer of blood vessels responsible for providing nourishment to the retina). A muscle integrity test is done with a moving object, and the ability to follow this object is evaluated. Refractive tests assess how well light waves are bent as they go through the cornea and the lens and the results of these tests help to determine which lens prescription will be needed. Presbyopia cannot be prevented as it is an inevitable part of aging.

Continued in the report…..

Presbyopia Treatment

The goal of treatment is to compensate for the inability of your eyes to focus on nearby objects. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents. The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, and nepafenac as their main ingredient. They target the ciliary muscles and change the pupil size and elasticity thereby improving the near vision. Recently the US FDA approved Vuity developed by AbbVie for the treatment of presbyopia in adults.

Continued in the report…..

Presbyopia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Presbyopia, total diagnosed cases of Presbyopia, total age-specific cases of Presbyopia, gender-specific cases of Presbyopia, and severity-specific cases of Presbyopia scenario of Presbyopia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

Total prevalent cases of Presbyopia in the 7MM were found to be 289,136,235 cases in 2021. These cases are expected to change by 2032 at a CAGR of 1.4% during the study period (2019–2032).
Among 7MM, the United States has the highest number of prevalent cases of Presbyopia with 118,346,762 cases in 2021.
Assessments as per DelveInsight’s analysts show that in 2021, in the United States, the severity-specific cases of Presbyopia were 20,301,021 and 81,204,086 cases for mild and moderate to severe cases, respectively which are expected to rise significantly by 2032.
In the US, the total age-specific cases of Presbyopia were 28,859,295, 33,190,032, 24,012,555, and 15,443,224 cases for the age group less than 60 years, 60–69 years, 70–79 years, and ≥80 years respectively, in the year 2021. These cases are expected to rise significantly by 2032.
In EU-5, Germany had the highest prevalent population of Presbyopia with 36,822,212 cases, followed by Italy with 27,683,651 cases in 2021. On the other hand, Spain had the lowest prevalent population for 2021.
In 2021, Japan had 34,568,372 total prevalent cases of Presbyopia.

Country-Wise Presbyopia Epidemiology

The epidemiology segment also provides the Presbyopia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Presbyopia Drug Chapters

The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Presbyopia Marketed Drugs

Vuity: AbbVie

Vuity (AGN-190584), developed by Allergan (which was acquired by AbbVie), is a miotic 1.25% pilocarpine hydrochloride ophthalmic solution for the treatment of presbyopia in adults. It is a topical, once-daily drop delivered by a proprietary vehicle that uses PhAST technology for rapid adjustment to the physiologic pH of the tear film. It is the first and only FDA-approved eye drop to treat presbyopia. Based on the recently announced Phase III Virgo trial results, AbbVie plans to submit a supplemental New Drug Application to the US FDA in the second quarter of 2022 for an optional twice-daily administration of Vuity for the treatment of presbyopia in adults.